Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaEur Urol 2022 Jul 14;[EPub Ahead of Print], J Bedke, BI Rini, ER Plimack, V Stus, R Gafanov, T Waddell, D Nosov, F Pouliot, D Soulières, B Melichar, I Vynnychenko, SJ Azevedo, D Borchiellini, RS McDermott, S Tamada, AM Nguyen, S Wan, RF Perini, L Rhoda Molife, MB Atkins, T Powles
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.